Andres Yarur
Cedars-Sinai Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andres Yarur as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06976853 · Moving Beyond Inflammation as a Therapeutic Target for Crohn's DiseaseWashington University School of Medicine · recruiting · Crohn Disease (CD) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:35 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 334 citationsRCR 39.3
- Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.J Crohns Colitis · 202441 citationsRCR 8.0
- ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse.Clin Gastroenterol Hepatol · 202426 citationsRCR 4.8
- Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.Lancet Gastroenterol Hepatol · 202525 citationsRCR 7.7
- 17 citationsRCR 2.9
- Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.J Crohns Colitis · 202416 citationsRCR 3.0
- The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.J Crohns Colitis · 202412 citationsRCR 1.7
- Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.J Crohns Colitis · 202412 citationsRCR 1.9
- Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program.Inflamm Bowel Dis · 20255 citationsRCR 1.5
- Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.Inflamm Bowel Dis · 20253 citationsRCR 1.0